$AUPH For the folks misconstruing PG’s “inorganic growth” comment, let me remind you of the events involving $CELG They too made some acquisitions and a year later, $BMY gobbled them up. The Juno deal was for $9B and $CELG ended up getting sold for $74B. Caforio stressed that the deal was about science and innovation. Aurinia acquired 2 important assets for $7M back in August (BAFF/APRIL, therapeutic target for SLE). BMY looking to enter Lupus space in a big way as proof of Deucravacitinib trials (which are not proving to be so hot lately). Maybe, just maybe someone directed PG to acquire them. “Read between the f’n lines” barrons.com/articles/celgen...
Celgene & Juno: The Latest in a Bumper Crop of Biotech M&A?via: Barrons